vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and NCS Multistage Holdings, Inc. (NCSM). Click either name above to swap in a different company.

NCS Multistage Holdings, Inc. is the larger business by last-quarter revenue ($50.6M vs $44.9M, roughly 1.1× AbCellera Biologics Inc.). NCS Multistage Holdings, Inc. runs the higher net margin — 29.5% vs -19.9%, a 49.5% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 12.5%). NCS Multistage Holdings, Inc. produced more free cash flow last quarter ($12.9M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 7.4%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

NCS Multistage Holdings, Inc. is a global oilfield services and energy technology provider specializing in engineered completion systems for onshore and offshore oil and gas production. It offers multistage fracturing tools that optimize well performance, serving major operators across North America, Latin America, the Middle East and Asia-Pacific, focusing on boosting operational efficiency and resource recovery for upstream energy clients.

ABCL vs NCSM — Head-to-Head

Bigger by revenue
NCSM
NCSM
1.1× larger
NCSM
$50.6M
$44.9M
ABCL
Growing faster (revenue YoY)
ABCL
ABCL
+775.9% gap
ABCL
788.4%
12.5%
NCSM
Higher net margin
NCSM
NCSM
49.5% more per $
NCSM
29.5%
-19.9%
ABCL
More free cash flow
NCSM
NCSM
$57.5M more FCF
NCSM
$12.9M
$-44.6M
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
7.4%
NCSM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABCL
ABCL
NCSM
NCSM
Revenue
$44.9M
$50.6M
Net Profit
$-8.9M
$15.0M
Gross Margin
Operating Margin
-63.7%
10.3%
Net Margin
-19.9%
29.5%
Revenue YoY
788.4%
12.5%
Net Profit YoY
73.9%
331.0%
EPS (diluted)
$-0.03
$5.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
NCSM
NCSM
Q4 25
$44.9M
$50.6M
Q3 25
$9.0M
$46.5M
Q2 25
$17.1M
$36.5M
Q1 25
$4.2M
$50.0M
Q4 24
$5.0M
$45.0M
Q3 24
$6.5M
$44.0M
Q2 24
$7.3M
$29.7M
Q1 24
$10.0M
$43.9M
Net Profit
ABCL
ABCL
NCSM
NCSM
Q4 25
$-8.9M
$15.0M
Q3 25
$-57.1M
$3.8M
Q2 25
$-34.7M
$924.0K
Q1 25
$-45.6M
$4.1M
Q4 24
$3.5M
Q3 24
$-51.1M
$4.1M
Q2 24
$-36.9M
$-3.1M
Q1 24
$-40.6M
$2.1M
Operating Margin
ABCL
ABCL
NCSM
NCSM
Q4 25
-63.7%
10.3%
Q3 25
-851.8%
6.6%
Q2 25
-290.2%
-5.6%
Q1 25
-1479.6%
8.6%
Q4 24
6.5%
Q3 24
-1439.4%
6.9%
Q2 24
-1276.2%
-14.0%
Q1 24
-551.5%
5.7%
Net Margin
ABCL
ABCL
NCSM
NCSM
Q4 25
-19.9%
29.5%
Q3 25
-637.8%
8.2%
Q2 25
-203.3%
2.5%
Q1 25
-1077.2%
8.1%
Q4 24
7.7%
Q3 24
-785.4%
9.4%
Q2 24
-504.3%
-10.4%
Q1 24
-408.0%
4.7%
EPS (diluted)
ABCL
ABCL
NCSM
NCSM
Q4 25
$-0.03
$5.43
Q3 25
$-0.19
$1.37
Q2 25
$-0.12
$0.34
Q1 25
$-0.15
$1.51
Q4 24
$1.34
Q3 24
$-0.17
$1.60
Q2 24
$-0.13
$-1.21
Q1 24
$-0.14
$0.82

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
NCSM
NCSM
Cash + ST InvestmentsLiquidity on hand
$128.5M
$36.7M
Total DebtLower is stronger
$5.3M
Stockholders' EquityBook value
$966.9M
$126.2M
Total Assets
$1.4B
$181.2M
Debt / EquityLower = less leverage
0.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
NCSM
NCSM
Q4 25
$128.5M
$36.7M
Q3 25
$83.2M
$25.3M
Q2 25
$92.4M
$25.4M
Q1 25
$159.3M
$23.0M
Q4 24
$156.3M
$25.9M
Q3 24
$126.6M
$15.3M
Q2 24
$148.3M
$18.6M
Q1 24
$123.6M
$14.0M
Total Debt
ABCL
ABCL
NCSM
NCSM
Q4 25
$5.3M
Q3 25
$5.1M
Q2 25
$5.5M
Q1 25
$5.4M
Q4 24
$6.0M
Q3 24
$6.5M
Q2 24
$6.8M
Q1 24
$6.4M
Stockholders' Equity
ABCL
ABCL
NCSM
NCSM
Q4 25
$966.9M
$126.2M
Q3 25
$964.0M
$110.1M
Q2 25
$1.0B
$106.4M
Q1 25
$1.0B
$103.2M
Q4 24
$1.1B
$98.8M
Q3 24
$1.1B
$96.0M
Q2 24
$1.1B
$91.0M
Q1 24
$1.1B
$93.7M
Total Assets
ABCL
ABCL
NCSM
NCSM
Q4 25
$1.4B
$181.2M
Q3 25
$1.4B
$162.0M
Q2 25
$1.4B
$158.0M
Q1 25
$1.3B
$155.1M
Q4 24
$1.4B
$152.8M
Q3 24
$1.4B
$145.8M
Q2 24
$1.4B
$139.4M
Q1 24
$1.5B
$140.9M
Debt / Equity
ABCL
ABCL
NCSM
NCSM
Q4 25
0.04×
Q3 25
0.05×
Q2 25
0.05×
Q1 25
0.05×
Q4 24
0.06×
Q3 24
0.07×
Q2 24
0.08×
Q1 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
NCSM
NCSM
Operating Cash FlowLast quarter
$-34.7M
$13.1M
Free Cash FlowOCF − Capex
$-44.6M
$12.9M
FCF MarginFCF / Revenue
-99.4%
25.5%
Capex IntensityCapex / Revenue
21.9%
0.4%
Cash ConversionOCF / Net Profit
0.88×
TTM Free Cash FlowTrailing 4 quarters
$-174.1M
$21.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
NCSM
NCSM
Q4 25
$-34.7M
$13.1M
Q3 25
$-52.6M
$7.2M
Q2 25
$-32.4M
$3.5M
Q1 25
$-11.6M
$-1.6M
Q4 24
$-108.6M
$10.6M
Q3 24
$-28.9M
$-2.0M
Q2 24
$-30.0M
$6.0M
Q1 24
$-41.7M
$-1.9M
Free Cash Flow
ABCL
ABCL
NCSM
NCSM
Q4 25
$-44.6M
$12.9M
Q3 25
$-61.5M
$6.9M
Q2 25
$-45.8M
$3.2M
Q1 25
$-22.2M
$-2.1M
Q4 24
$-187.0M
$10.4M
Q3 24
$-47.4M
$-2.5M
Q2 24
$-50.1M
$5.6M
Q1 24
$-65.8M
$-2.2M
FCF Margin
ABCL
ABCL
NCSM
NCSM
Q4 25
-99.4%
25.5%
Q3 25
-687.0%
14.9%
Q2 25
-267.9%
8.9%
Q1 25
-524.0%
-4.2%
Q4 24
-3702.8%
23.1%
Q3 24
-728.4%
-5.6%
Q2 24
-683.8%
19.0%
Q1 24
-661.5%
-5.0%
Capex Intensity
ABCL
ABCL
NCSM
NCSM
Q4 25
21.9%
0.4%
Q3 25
99.7%
0.5%
Q2 25
78.2%
0.8%
Q1 25
251.1%
0.9%
Q4 24
1552.7%
0.5%
Q3 24
284.6%
1.0%
Q2 24
274.6%
1.1%
Q1 24
242.5%
0.7%
Cash Conversion
ABCL
ABCL
NCSM
NCSM
Q4 25
0.88×
Q3 25
1.88×
Q2 25
3.81×
Q1 25
-0.41×
Q4 24
3.07×
Q3 24
-0.49×
Q2 24
Q1 24
-0.91×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABCL
ABCL

Segment breakdown not available.

NCSM
NCSM

Products$33.8M67%
Services$16.8M33%

Related Comparisons